Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor (CAAR) T cells that are designed to selectively bind and eliminate B cells, which produce disease-causing autoantibodies or pathogenic B cells. The company's lead product candidate is DSG3-CAART, which is in Phase I clinical trial for the treatment of mucosal pemphigus vulgaris, an autoimmune blistering skin disease, and Hemophilia A with Factor VIII alloantibodies. Its product candidate pipeline also includes MuSK-CAART, a preclinical stage product to treat a subset of patients with myasthenia gravis; FVIII-CAART, a discovery stage product to treat a subset of patients with Hemophilia A; and DSG3/1-CAART, a discovery stage product for the treatment of mucocutaneous pemphigus vulgaris. It has a collaboration with the University of Pennsylvania; and research agreement with The Regents of the University of California. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.

Cabaletta Bio, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

REGISTRATIONAL RESET-MYOSITIS  CLINICAL DATA ON TRACK TO BE REPORTED IN MID-2027 TO SUPPORT 2H27 BLA SUBMISSION FOR RESE-CEL

CABALETTA BIO REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

83% OF DERMATOMYOSITIS PATIENTS IN THE PHASE 1/2 RESET-MYOSITIS STUDY WOULD HAVE MET THE REGISTRATIONAL PRIMARY ENDPOINT; ALL THESE PATIENTS MAINTAINED THEIR RESPONSE OFF IMMUNOMODULATORS THROUGH LATEST FOLLOW-UP, AS LONG AS 1.5 YEARS

CABALETTA BIO ANNOUNCES NEW RESE-CEL DATA AND DEVELOPMENT UPDATES ACROSS AUTOIMMUNE PORTFOLIO, INCLUDING ENCOURAGING EARLY PC-FREE LUPUS FINDINGS, AT EULAR 2026 CONGRESS

PRECONDITIONING-FREE (PC-FREE) 6-TO-9-MONTH CLINICAL DATA WITH A SINGLE INFUSION OF THE LOWEST DOSE OF RESE-CEL IN THE RESET-PV  STUDY PRESENTED TODAY AT ASGCT 2026 ANNUAL MEETING ALONG WITH INITIAL RESE-CEL TRANSLATIONAL DATA USING CELLARES' INDUSTRIALIZED, AUTOMATED MANUFACTURING

CABALETTA BIO REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

A SINGLE INFUSION OF THE LOWEST DOSE OF RESE-CEL ADMINISTERED WITHOUT PRECONDITIONING, AFTER DISCONTINUATION OF ALL IMMUNOMODULATORS, DEMONSTRATED COMPELLING DRUG-FREE RESPONSES FOR 6 MONTHS IN 2 OF 4 REFRACTORY PATIENTS; NEXT DOSE COHORT ACTIVELY ENROLLING TRANSLATIONAL DATA FROM THE FIRST TWO PATIENTS DOSED WITH RESE-CEL MANUFACTURED ON THE AUTOMATED CELL SHUTTLE PLATFORM SHOWED PHARMACOKINETIC AND PHARMACODYNAMIC DATA CONSISTENT WITH OTHER PATIENTS DOSED IN THE RESET CLINICAL PROGRAM ASGCT 2026 PRESENTATIONS REINFORCE CABALETTA'S FOCUS ON OPTIMIZING THE PATIENT AND PHYSICIAN EXPERIENCE THROUGH SIMPLIFIED TREATMENT REGIMENS AND SCALABLE RELIABLE MANUFACTURING PHILADELPHIA, MAY 14, 2026 (GLOBE NEWSWIRE) -- CABALETTA BIO, INC. (NASDAQ: CABA), A LATE-STAGE CLINICAL BIOTECHNOLOGY COMPANY FOCUSED ON DEVELOPING AND LAUNCHING TARGETED CELL THERAPIES DESIGNED SPECIFICALLY FOR PATIENTS WITH AUTOIMMUNE DISEASES, TODAY ANNOUNCED NEW CLINICAL AND TRANSLATIONAL DATA FROM THE FIRST FOUR PATIENTS IN THE LOWEST DOSE COHORT IN RESET-PV EVALUATING PRECONDITIONING-FREE (PC-FREE) RESE-CEL (RESECABTAGENE AUTOLEUCEL) AND INITIAL MANUFACTURING AND TRANSLATIONAL DATA FROM THE FIRST TWO AUTOIMMUNE PATIENTS TREATED WITH RESE-CEL MANUFACTURED USING THE AUTOMATED CELLARES CELL SHUTTLE PLATFORM IN THE RESET CLINICAL DEVELOPMENT PROGRAM. THESE DATA ARE BEING PRESENTED IN SEPARATE POSTER PRESENTATIONS TODAY AT THE AMERICAN SOCIETY OF GENE & CELL THERAPY (ASGCT) 2026 ANNUAL MEETING IN BOSTON, MA.

CABALETTA BIO PRESENTS PRECONDITIONING-FREE CLINICAL DATA AND AUTOMATED MANUFACTURING TRANSLATIONAL DATA FOR RESE-CEL AT ASGCT 2026 ANNUAL MEETING

PHILADELPHIA, MAY 04, 2026 (GLOBE NEWSWIRE) -- CABALETTA BIO, INC. (CABALETTA OR THE COMPANY) (NASDAQ: CABA), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY FOCUSED ON DEVELOPING AND LAUNCHING CURATIVE TARGETED CELL THERAPIES DESIGNED SPECIFICALLY FOR PATIENTS WITH AUTOIMMUNE DISEASES, ANNOUNCED TODAY THE PRICING OF AN UNDERWRITTEN OFFERING OF 51,725,000 SHARES OF COMMON STOCK. THE AGGREGATE GROSS PROCEEDS FROM THE OFFERING, BEFORE DEDUCTING UNDERWRITING DISCOUNTS AND COMMISSIONS AND OFFERING EXPENSES, ARE EXPECTED TO BE APPROXIMATELY $150 MILLION. THE OFFERING IS EXPECTED TO CLOSE ON OR ABOUT MAY 5, 2026, SUBJECT TO THE SATISFACTION OF CUSTOMARY CLOSING CONDITIONS. THE FINANCING INCLUDED PARTICIPATION FROM BAIN CAPITAL LIFE SCIENCES, ADAGE CAPITAL MANAGEMENT, CORMORANT ASSET MANAGEMENT AND OTHER EXISTING INVESTORS, MULTIPLE NEW MUTUAL AND SOVEREIGN WEALTH FUNDS AND ELI LILLY AND COMPANY.

CABALETTA BIO ANNOUNCES PRICING OF $150 MILLION UNDERWRITTEN OFFERING

AGREEMENT FACILITATES FLEXIBLE, SCALABLE AUTOMATED INDUSTRIALIZED PRODUCTION OF RESE-CEL FOR MANY THOUSANDS OF PATIENTS PER YEAR AT A COST PER BATCH THAT IS AMONG THE LOWEST IN THE INDUSTRY INITIAL TRANSLATIONAL DATA FROM THE FIRST TWO PATIENTS DOSED WITH RESE-CEL MANUFACTURED BY CELLARES WILL BE PRESENTED AT THE ASGCT CONFERENCE IN MAY PHILADELPHIA AND SOUTH SAN FRANCISCO, CALIF., APRIL 28, 2026 (GLOBE NEWSWIRE) -- CABALETTA BIO, INC. (NASDAQ: CABA), A LATE-STAGE CLINICAL BIOTECHNOLOGY COMPANY FOCUSED ON DEVELOPING AND LAUNCHING CURATIVE TARGETED CELL THERAPIES DESIGNED SPECIFICALLY FOR PATIENTS WITH AUTOIMMUNE DISEASES, AND CELLARES, THE FIRST INTEGRATED DEVELOPMENT AND MANUFACTURING ORGANIZATION (IDMO), TODAY ANNOUNCED A COMMERCIAL AGREEMENT TO SUPPLY RESE-CEL (RESECABTAGENE AUTOLEUCEL) USING CELLARES' AUTOMATED CELL SHUTTLE AND THROUGH FUTURE IMPLEMENTATION OF CELLARES' CELL Q PLATFORM.

CABALETTA BIO AND CELLARES ANNOUNCE 10-YEAR COMMERCIAL SUPPLY AGREEMENT FOR RESE-CEL

SOUTH SAN FRANCISCO, CALIF.--(BUSINESS WIRE)--CELLARES, THE FIRST INTEGRATED DEVELOPMENT AND MANUFACTURING ORGANIZATION (IDMO), TODAY ANNOUNCED IT HAS ENTERED INTO A 10-YEAR COMMERCIAL SUPPLY AGREEMENT WITH CABALETTA BIO INC. (NASDAQ: CABA) FOR THE AUTOMATED MANUFACTURE OF RESE-CEL (RESECABTAGENE AUTOLEUCEL), CABALETTA'S INVESTIGATIONAL CAR T CELL THERAPY FOR AUTOIMMUNE DISEASES. THE AGREEMENT SECURES THE LONG-TERM MANUFACTURING CAPACITY AND SUPPLY PREDICTABILITY REQUIRED TO ADDRESS THE GLOBAL.

CELLARES AND CABALETTA BIO SIGN 10-YEAR COMMERCIAL SUPPLY AGREEMENT TO SCALE RESE-CEL

PHILADELPHIA, APRIL 27, 2026 (GLOBE NEWSWIRE) -- CABALETTA BIO, INC. (NASDAQ: CABA), A LATE-STAGE CLINICAL BIOTECHNOLOGY COMPANY FOCUSED ON DEVELOPING AND LAUNCHING TARGETED CELL THERAPIES DESIGNED SPECIFICALLY FOR PATIENTS WITH AUTOIMMUNE DISEASES, TODAY ANNOUNCED MULTIPLE UPCOMING PRESENTATIONS INCLUDING MANUFACTURING, TRANSLATIONAL AND CLINICAL DATA ON RESE-CEL (RESECABTAGENE AUTOLEUCEL) AT THE AMERICAN SOCIETY OF GENE & CELL THERAPY (ASGCT) 2026 ANNUAL MEETING, BEING HELD FROM MAY 11-15, 2026, IN BOSTON, MA.

CABALETTA BIO ANNOUNCES MULTIPLE UPCOMING PRESENTATIONS, INCLUDING DATA ON RESE-CEL WITHOUT PRECONDITIONING AND RESE-CEL WITH AUTOMATED MANUFACTURING, AT THE ASGCT 2026 ANNUAL MEETING

SOUTH SAN FRANCISCO, CALIF.--(BUSINESS WIRE)--CELLARES, THE FIRST INTEGRATED DEVELOPMENT AND MANUFACTURING ORGANIZATION (IDMO), TODAY ANNOUNCED THAT CABALETTA BIO INC.'S (CABALETTA BIO OR CABALETTA) (NASDAQ: CABA) INVESTIGATIONAL CAR T CELL THERAPY RESE-CEL (RESECABTAGENE AUTOLEUCEL) HAS BEEN INFUSED INTO THE FIRST TWO PATIENTS USING DRUG PRODUCT MANUFACTURED ON CELLARES' CELL SHUTTLE AUTOMATED MANUFACTURING PLATFORM. THE ADMINISTRATION OF AN AUTOLOGOUS CELL THERAPY, WHICH MET ALL RELEASE.

FIRST PATIENTS DOSED WITH CABALETTA BIO'S RESE-CEL MANUFACTURED ON CELLARES' AUTOMATED CELL SHUTTLE PLATFORM

RESE-CEL MYOSITIS BLA SUBMISSION ON TRACK FOR 2027 BASED ON A 17-PATIENT, SINGLE ARM REGISTRATIONAL COHORT DESIGN, INCLUDING AN OUTPATIENT DOSING OPTION

Cabaletta Bio, Inc.

CABA

Price

Financial Reports

No items found.

Press Releases

Cabaletta Bio, Inc.

CABA.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

CABA